Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

ABSTRACT:

Background

ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this study was to determine whether cannabinoids might constitute a new therapeutic tool for the treatment of ErbB2-positive breast tumors. We analyzed their antitumor potential in a well established and clinically relevant model of ErbB2-driven metastatic breast cancer: the MMTV-neu mouse. We also analyzed the expression of cannabin

SUBMITTER: Caffarel MM 

PROVIDER: S-EPMC2917429 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature